Patents by Inventor Tim SCHNYDER

Tim SCHNYDER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180237495
    Abstract: Provided herein are specific CD137 receptor agonist proteins, nucleic acids encoding the same, and methods of treating a subject having a CD137L-associated disease or disorder. The CD137 receptor agonist proteins provided herein comprise three soluble CD137L domains and an Fe fragment. The CD137 receptor agonist proteins are substantially non-aggregating and suitable for therapeuctic, diagnostic and/or research applications.
    Type: Application
    Filed: April 17, 2018
    Publication date: August 23, 2018
    Inventors: Christian GIEFFERS, Oliver HILL, Meinolf THIEMANN, Tim SCHNYDER
  • Publication number: 20180230196
    Abstract: Provided herein are specific OX40 receptor agonist proteins, nucleic acids encoding the same, and methods of treating a subject having an OX40L-associated disease or disorder. The OX40 receptor agonist proteins provided herein comprise three soluble OX40L domains and an FE fragment. The OX40 receptor agonist proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.
    Type: Application
    Filed: April 17, 2018
    Publication date: August 16, 2018
    Inventors: Christian GIEFFERS, Oliver HILL, Meinolf THIEMANN, Tim SCHNYDER
  • Publication number: 20180208664
    Abstract: The present invention relates to a specific CD95L antibody and to the use thereof in the treatment or diagnosis of diseases involving CD95L-induced signalling, e.g. cancer diseases.
    Type: Application
    Filed: March 21, 2018
    Publication date: July 26, 2018
    Inventors: Christian GIEFFERS, Oliver HILL, Meinolf THIEMANN, Jaromir SYKORA, Christian MERZ, Tim SCHNYDER, Harald FRICKE
  • Publication number: 20180066036
    Abstract: Provided herein are specific CD40 receptor agonist proteins, nucleic acids encoding the same, and methods of treating a subject having a CD40L-associated disease or disorder. The CD40 receptor agonist proteins provided herein comprise three soluble CD40L domains and an Fc fragment. The CD40 receptor agonist proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.
    Type: Application
    Filed: October 26, 2017
    Publication date: March 8, 2018
    Inventors: Oliver HILL, Christian GIEFFERS, Meinolf THIEMANN, Tim SCHNYDER